Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Amir Harandi, Aisha S Zaidi, Abigail M Stocker, Damian A Laber, Amir Harandi, Aisha S Zaidi, Abigail M Stocker, Damian A Laber

Abstract

Epidermal growth factor receptor (EGFR) is a cell surface molecule and member of the ErbB family of receptor tyrosine kinases. Its activation leads to proliferation, antiapoptosis, and metastatic spread, making inhibition of this pathway a compelling target. In recent years, an increasing number of clinical trials in the management of solid malignancies have become available indicating the clinical efficacy of anti-EGFR monoclonal antibodies and oral small molecule tyrosine kinase inhibitors (TKIs). This review addresses frequently used EGFR inhibitors, summarizes clinical efficacy data of these new therapeutic agents, and discusses their associated toxicity and management.

References

    1. Sporn MB, Todaro GJ. Autocrine secretion and malignant transformation of cells. The New England Journal of Medicine. 1980;303(15):878–880.
    1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology/Hematology. 1995;19(3):183–232.
    1. Citri A, Yarden Y. EGF-ERBB randomize: towards the systems level. Nature Reviews Molecular Cell Biology. 2006;7(7):505–516.
    1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. 2005;5(5):341–354.
    1. Khazaeli MB, LoBuglio AF, Falcey JW, et al. Low immunogenicity of a chimeric monoclonal antibody (MoAB), IMC-C225, used to treat epidermal growth factor receptor-positive tumors. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology; May 2000; New Orleans, La, USA. abstract no. 207a.
    1. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocrine-Related Cancer. 2003;10(1):1–21.
    1. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer. 2007;7(3):169–181.
    1. Zandi R, Larsen AB, Andersen P, Stockhausen M-T, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cellular Signalling. 2007;19(10):2013–2023.
    1. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Research. 1984;44(3):1002–1007.
    1. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. Journal of Clinical Oncology. 2002;20(supplement 18):1S–13S.
    1. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology. 2005;23(25):5892–5899.
    1. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Journal of Clinical Oncology. 2001;19(13):3267–3279.
    1. Pérez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clinical Lung Cancer. 2004;6(supplement 1):S20–S23.
    1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine. 2005;353(2):123–132.
    1. Paz-Ares L, Sanchez JM, García-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) Journal of Clinical Oncology. 2006;24(supplement 18)
    1. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 2007;25(15):1960–1966.
    1. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology. 2003;21(12):2237–2246.
    1. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Journal of the American Medical Association. 2003;290(16):2149–2158.
    1. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) The Lancet. 2005;366(9496):1527–1537.
    1. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. Journal of Clinical Oncology. 2004;22(5):777–784.
    1. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. Journal of Clinical Oncology. 2004;22(5):785–794.
    1. Kelly K, Gaspar L, Chansky K, Albain KS, Crowley J, Gandara DR. Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology; May 2005; Orlando, Fla, USA. abstract no. 7058.
    1. Mok TS, Leong S, Liu X, et al. Gefitinib vs carboplatin/paclitaxel in clinically selected chemonaive patients with advanced non-small cell lung cancer in Asia (ipass): randomized, open-label, phase III study. In: Proceedings of the 33rd European Society for Medical Oncology (ESMO '08); September 2008; Stockholm, Sweden.
    1. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. The New England Journal of Medicine. 2008;358(11):1160–1174.
    1. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. The New England Journal of Medicine. 2007;357(20):2040–2048.
    1. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. The New England Journal of Medicine. 2004;351(4):337–345.
    1. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2008;26(14):2311–2319.
    1. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Journal of Clinical Oncology. 2007;25(supplement 18) abstract no. 4000.
    1. Bokemeyer C, Bondarenko I, Hartmann JT, et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. In: Proceedings of the 44th Annual Meeting of the American Society of Clinical Oncology; May-June 2008; Chicago, Ill, USA. abstract no. 4000.
    1. Van Cutsem E, Lang I, D'haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. In: Proceedings of the 44th Annual Meeting of the American Society of Clinical Oncology; May-June 2008; Chicago, Ill, USA. abstract no. 2.
    1. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2008;26(10):1626–1634.
    1. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarvala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. Journal of Clinical Oncology. 2004;22(1):77–85.
    1. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. The New England Journal of Medicine. 2008;359(11):1116–1127.
    1. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology. 2005;23(34):8646–8654.
    1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine. 2006;354(6):567–578.
    1. Bloomston M, Bhardwaj A, Ellison EC, Frankel WL. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Digestive Surgery. 2006;23(1-2):74–79.
    1. Tsiambas E, Karameris A, Lazaris AC, et al. EGFR alterations in pancreatic ductal adenocarcinoma: a chromogenic in situ hybridization analysis based on tissue microarrays. Hepato-Gastroenterology. 2006;53(69):452–457.
    1. Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. Journal of Clinical Oncology. 2007;25:p. 199s.
    1. Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 2008;26(supplement 15) abstract no. 3.
    1. Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. Journal of Clinical Oncology. 2008;26(20):3351–3357.
    1. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: panitumumab (VectibixTM) The Oncologist. 2007;12(5):577–583.
    1. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer. 2007;110(5):980–988.
    1. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology. 2007;25(13):1658–1664.
    1. Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Annals of Oncology. 2008;19(1):92–98.
    1. Hecht JR, Mitchell E, Chidiac T, et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/− panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). In: Proceedings of the Gastrointestinal Cancers Symposium; January 2008; Orlando, Fla, USA. abstract no. 273.
    1. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? Journal of Clinical Pathology. 2004;57(7):773–775.
    1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced renal cell carcinoma. The New England Journal of Medicine. 2007;356(2):125–134.
    1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine. 2008;359(4):378–390.
    1. Cheng A, Kang Y, Chen Z, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology. 2008;26(supplement 15) abstract no. 4509.
    1. Abou-Alfa G, Johnson P, Knox J, et al. Preliminary results from a phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. European Journal of Cancer Supplements. 2007;5(4):p. 259. abstract no. 3500.
    1. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology. 2008;26(29):4714–4719.
    1. Zhong H, Bowen JP. Molecular design and clinical development of VEGFR kinase inhibitors. Current Topics in Medicinal Chemistry. 2007;7(14):1379–1393.
    1. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet. 2007;369(9555):29–36.
    1. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248,a multitargetted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology. 2006;24(1):16–24.
    1. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. Journal of the American Medical Association. 2006;295(21):2516–2524.
    1. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon alfa (IFN-a) as a first line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) The New England Journal of Medicine. 2007;356(2):115–124.
    1. Cella D, Li JZ, Cappelleri JC, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. Journal of Clinical Oncology. 2008;26(22):3763–3769.
    1. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. The Lancet. 2006;368(9544):1329–1338.
    1. Lin NU, Dieras V, Paul D, et al. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT) Journal of Clinical Oncology. 2007;25(supplement 18) abstract no. 1012.
    1. Ekenel M, Hormigo AM, Peak S, DeAngelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. Journal of Neuro-Oncology. 2007;85(2):223–227.
    1. Geyer CE, Jr., Martin A, Newstat B, et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): genomic and updated efficacy data. Journal of Clinical Oncology. 2007;25(supplement 18) abstract no.1035.
    1. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology. 1999;17(9):2639–2648.
    1. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology. 2002;20(3):719–726.
    1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine. 2001;344(11):783–792.
    1. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England Journal of Medicine. 2005;353(16):1673–1684.
    1. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to transtuzumab (Herceptin) Journal of the National Cancer Institute. 2001;93(24):1852–1857.
    1. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. The New England Journal of Medicine. 2006;355(26):2733–2743.
    1. Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. Journal of Clinical Oncology. 2008;26(34):5544–5552.
    1. O'Keefe E, Battin T, Payne R., Jr. Epidermal growth factor receptor in human epidermal cells: direct demonstration in cultured cells. Journal of Investigative Dermatology. 1982;78(6):482–487.
    1. Nanney LB, McKanna JA, Stoscheck CM, Carpenter G, King LE., Jr. Visualization of epidermal growth factor receptors in human epidermis. Journal of Investigative Dermatology. 1984;82(2):165–169.
    1. Green MR, Phil D, Couchman JR. Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition. Journal of Investigative Dermatology. 1985;85(3):239–245.
    1. Piérard-Franchimont C, Colige A, Arrese Estrada J, Lapière CM, Piérard GE. Immunohistochemical expression of epidermal growth factor receptors in nuclei of a subpopulation of keratinocytes and sweat gland cells. Dermatologica. 1991;183(1):7–9.
    1. Nanney LB, Stoscheck CM, King LE, Jr., Underwood RA, Holbrook KA. Immunolocalization of epidermal growth factor receptors in normal developing human skin. Journal of Investigative Dermatology. 1990;94(6):742–748.
    1. Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumors. British Journal of Dermatology. 2004;151(1):238–241.
    1. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the pidermal growth factor receptor. Journal of Clinical Oncology. 2004;22(7):1201–1208.
    1. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. Journal of Clinical Oncology. 2004;22(13):2610–2616.
    1. Pérez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. The Oncologist. 2005;10(5):345–356.
    1. Galimont-Collen AFS, Vos LE, Lavrijsen APM, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. European Journal of Cancer. 2007;43(5):845–851.
    1. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the RAF kinase and VEGFR inhibitor sorafenib (BAY-43-9006) in patients with advanced renal cell cancer (RCC). In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology; May 2005; Orlando, Fla, USA. abstract no. 4510.
    1. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. The Journal of the American Medical Association. 2006;295(21):2516–2524.
    1. Mak KKL, Chan SY. Epidermal growth factor as a biologic switch in hair growth cycle. The Journal of Biological Chemistry. 2003;278(28):26120–26126.
    1. Murillas R, Larcher F, Conti CJ, Santos M, Ullrich A, Jorcano JL. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO Journal. 1995;14(21):5216–5223.
    1. YM BioSciences Inc. January 2009, .
    1. Uribe JM, Gelbmann CM, Traynor-Kaplan AE, Barrett KE. Epidermal growth factor inhibits Ca2+-dependent Cl− transport in T84 human colonic epithelial cells. American Journal of Physiology. 1996;271(3):C914–C922.
    1. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa®) tablets. The Oncologist. 2003;8(4):303–306.
    1. Iressa [package insert] AstraZeneca, London, UK, 2003.
    1. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer. 2004;45(1):93–104.
    1. Makris D, Scherpereel A, Copin MC, et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer. 2007;7, article 150:1–4.
    1. Lind JS, Smit EF, Grünberg K, Senan S, Lagerwaard FJ. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. Journal of Thoracic Oncology. 2008;3(9):1050–1053.
    1. Spigel DR, Lin M, O'Neill V, Hainsworth JD. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer. 2008;112(12):2749–2755.
    1. Pfizer. Sutent (sunitinib) Prescribing Information, 2007.
    1. Perez EA, Byrne JA, Isaac W, et al. Cardiac safety experience in 3127 patients treated with lapatinib. Annals of Oncology. 2006;17(supplement 9)
    1. Lenz H-J. Management and preparedness for infusion and hypersensitivity reactions. The Oncologist. 2007;12(5):601–609.
    1. Melichar B, Cerman J, Jr., Malířová E. Successful management of infusion reaction accompanying the start of cetuximab therapy. Supportive Care in Cancer. 2007;15(4):445–449.
    1. Needle MN. Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Seminars in Oncology. 2002;29(5) supplement 14:55–60.
    1. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3- galactose. The New England Journal of Medicine. 2008;358(11):1109–1117.
    1. Saif MW, Cohenuram M. Role of panitumumab in the management of metastatic colorectal cancer of metastatic colorectal cancer. Clinical Colorectal Cancer. 2006;6(2):118–124.
    1. Saif MW, Peccerillo J, Potter V. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. Cancer Chemotherapy and Pharmacology. 2009;63(6):1017–1022.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren